Lin Wu is a seasoned leader in the field of molecular diagnostics and research and development, currently serving as Vice President and Head of R&D at Roche Diagnostics China since September 2021, with a focus on core lab development. Prior experience includes roles as Vice President at Roche Sequencing USA, overseeing global assay and platform development, where a team of approximately 300 scientists managed a $200 million R&D budget for next-generation sequencing (NGS) portfolios. Wu has been instrumental in launching innovative diagnostic products, such as the AVENIO ctDNA NGS assay, and has a proven track record in leading high-performance teams and driving product development strategies. Wu's extensive career at Roche Molecular Diagnostics led to significant advancements in companion diagnostic tests, receiving accolades for pioneering work in cancer management technologies. Educational qualifications include a Postdoctoral Fellowship at Princeton University, a Ph.D. from the University at Buffalo, and a Bachelor's degree from Fudan University.
This person is not in any teams
This person is not in any offices